EDGE MEDICAL-B (02675) has announced its intention to explore the initial proposal of issuing renminbi-denominated shares, initiating a plan for an initial public offering of ordinary shares on the A-share market (the proposed A-share listing). The proposed issuance of RMB shares is subject to and contingent upon, among other things, market conditions, further approval from the board of directors, approval from the company's shareholders at a general meeting, and approvals from necessary regulatory authorities.

In connection with the proposed A-share listing, the company has engaged a pre-listing tutoring institution and submitted a registration application for pre-listing tutoring on September 11, 2026. As of the date of this announcement, apart from the information disclosed herein, the board has not approved any other plans regarding the proposed A-share listing, nor has it filed any applications with relevant regulatory authorities in China or any other region for the proposed A-share listing.

Where to Begin

The company's move to initiate the A-share listing process marks a strategic step to broaden its capital base. The submission of the pre-listing tutoring registration is an early procedural milestone in this journey, aligning with standard practice for companies seeking to list on mainland exchanges.

Why Focus on This Development

This announcement underscores the company's proactive approach to exploring new financing avenues. Investors should note that the plan remains preliminary, with several approvals still pending, including internal board and shareholder consent, as well as regulatory clearance. Further details will emerge as the process advances, and the company has committed to keeping the market informed of any material updates.